Esiflo 250 Transhaler is a combination inhalation powder containing Salmeterol (25 mcg) and Fluticasone Propionate (250 mcg), indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta2-adrenergic receptor agonist that provides bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing bronchospasm. Fluticasone Propionate is a corticosteroid with potent anti-inflammatory properties that helps to decrease airway inflammation, reduce mucus production, and prevent exacerbations. The dual action of Esiflo 250 Transhaler targets both bronchoconstriction and underlying inflammation, contributing to improved respiratory function and symptom control. This medication is administered via a dry powder inhaler, ensuring efficient delivery of the active ingredients directly to the lungs. Esiflo 250 Transhaler is intended for regular use and is not suitable for relief of acute bronchospasm. Patients should be advised on proper inhaler technique to optimize therapeutic outcomes. Common side effects may include headache, throat irritation, and oral candidiasis, which can be minimized by rinsing the mouth after inhalation. Use of Esiflo 250 Transhaler should be under medical supervision, with periodic assessment to adjust therapy as needed.